Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, Oxford University Hospitals NHS Foundation Trust and the Patient experience healthcare company Oneview Healthcare signed a research and development (R&D) agreement for clinical pathways, following the success of a Prostate Cancer Pathway pilot.

Image courtesy of Medical Sciences Division and John Cairns

Oneview Healthcare PLC (Oneview) have announced a partnership with The Chancellor Masters and Scholars of the University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) to continue research and development on a clinical pathways product. The solution will ease administrative burden, digitise currently paper-based processes and ultimately expedite wait times and access to care.

In conjunction with a leading engineering company, University of Oxford, OUH and Oneview entered into a partnership in an agreement dated 31 January 2017 to pilot a digital pathways for prostate cancer to improve patient outcomes and deliver cost efficiencies to health systems. That pilot’s success is the catalyst for the new agreement. The prostate cancer pilot succeeded in the areas of clinical staff uptake, meeting or exceeding wait time goals, and providing an easy-to-use interface the clinicians embraced. The new research and development will focus on expanding the technology to include full commercial deployment at Oxford via a SMART on FHIR1 integration and expansion of scope to other types of  cancer (beyond prostate cancer). The partners expect to commercialise the new products globally, helping healthcare organisations around the world to digitise care pathways, connecting information across systems to drive clinical transformation and reduce variation.

Professor Freddie Hamdy, Head of Oxford University's Nuffield Department of Surgical Sciences and Divisional Director of Surgery and Oncology at OUH, commented: 'This is one of the most innovative projects Oxford have done in the past few years.'

James Fitter, CEO of Oneview Healthcare stated: 'This has been a textbook case of agile development with our team working side-by-side with the Oxford clinicians to solve real-world problems. Combining Oxford’s clinical expertise with our software innovation and integration skills has proved a powerful combination. We are delighted with the results of the pilot and the opportunity to move forward in developing other life-changing cancer pathways. We take pride in our partnership with Oxford University and OUH, and are honoured that we can all work together to advance technology that has so much potential to changes lives around the world.'

1 SMART on FHIR is an open standards-based platform for medical apps designed to promote interoperability

Press release courtsey of Oneview.

Similar stories

ASPI honours ProtecT Trial for pioneering research demonstrating the safety of active surveillance

The ProtecT Trial has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award for game-changing research in the development of the Active Surveillance approach to managing low-risk prostate cancer.